Phase II clinical trial with 5-fluorouracil, recombinant interferon-α-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus

Cancer

Volumn 78, Issue 1, 1996, Pages 30-34

  Wadler, Scott ^a,b   Haynes, Hilda ^a,b   Beitler, Jonathan J ^b   Hu, Xiaoping ^a,b   Fell, Stanley ^b   Camacho, Margarita ^b   Levine, Barry ^b   Wiernik, Peter H ^a,b  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

5 fluorouracil; Biochemical modulation; Cisplatin; Esophageal carcinoma; Interferon

Indexed keywords

CISPLATIN; FLUOROURACIL; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0029997118     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960701)78:1<30::AID-CNCR6>3.0.CO;2-L     Document Type: Article

References (20)

1. Earlam R, Cunha-Menlo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 1980;67:381-90.
2. Earlam R, Cunha-Menlo JR. Oesophageal squamous cell carcinoma: II. A clinical review of radiotherapy. Br J Surg 1980;67:457-61.
3. Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Hahn RG. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 1980;46:2149-53.
4. Wadler S, Fell S, Haynes H, Katz HJ, Rozenblitt A, Kaleya R, et al. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. Cancer 1993;71:1726-30.
5. Kelsen D, Lovett D, Wong J, Saltz L, Buckley M, Murray P, et al. Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol 1992;10:269-74.
6. Haller DG. Chemotherapy in gastrointestinal malignancies. Semin Oncol 1988; 15(4 Suppl):50-64.
7. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50:3473-86.
8. Beitler JJ, Wadler S, Haynes H, Fell S, Vikram B, Rozenblit A, et al. Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer. Med Oncol 1995;12:115-20.
9. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
10. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
11. Simon RM. Design and conduct of clinical trials. In: DeVita VT, Hellman S, Rosenberg S, editors. Cancer: Principles and Practice of Oncology. 3rd edition. New York: JB Lippincott, 1989:369-420.
12. Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y, Keresztes R, et al. A phase II trial of interferon alpha-2a, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer 1995;75:2197-202.
13. Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 1990;50:5735-9.
14. Schwartz EL, Hoffman M, O'Connor C, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-alfa in human colon carcinoma cells. Biochem Biophys Res Commun 1991;182:1232-9.
15. Schwartz EL, Baptiste N, O'Connor CJ, Wadler S, Otter B. Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary results on thymidine phosphorylase. Cancer Res 1994;54:1472-8.
16. Schwartz EL, Baptiste N, Wadler S, Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995;270: 19073-7.
17. Wadler S, Horowitz R, Mao X, Schwartz EL. Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA double strand breaks. Cancer Chemother Pharmacol in press.
18. Schwartz EL, Baptiste N, Wadler S. Mechanism of induction of thymidine phosphorylase expression by interferon-alpha in vitro and in vivo. Proc Am Assoc Cancer Res 1994;35:318.
19. Kelson DP, Minsky B, Smith M, Beitler J, Niedzwiecki D, Chapman D, et al. Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. J Clin Oncol 1990;8:1352-61.
20. Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology 1994;8:37-42.